Indraprastha Medical (INDRAMEDCO) Fundamentals 2026 — P/E 18.3x, Revenue Analysis | SniperIQ
Indraprastha Medical (INDRAMEDCO) is a India-listed Healthcare company in Medical - Care Facilities with a market capitalization of ₹3,369 Crore, trading at ₹367.45 on the NSE. This SniperIQ fundamentals page covers Indraprastha Medical's valuation (P/E 18.3x, P/B 4.5x), profitability (net margin 12.4%), revenue (₹1,483 Crore in FY2026), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Indraprastha Medical's market cap?
Indraprastha Medical (INDRAMEDCO) has a market capitalization of approximately ₹3,369 Crore, trading at ₹367.45 on the NSE. Market cap moves with the live share price.
What is Indraprastha Medical's P/E ratio?
Indraprastha Medical's trailing twelve-month P/E ratio is 18.3x, with a price-to-book (P/B) of 4.5x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Indraprastha Medical?
Indraprastha Medical runs a net profit margin of 12.4%, a gross margin of 34.8%, and an operating margin of 15.1%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Indraprastha Medical generate?
Indraprastha Medical reported revenue of ₹1,483 Crore for fiscal year 2026, with net income of ₹184 Crore and earnings per share (EPS) of 20.03. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Indraprastha Medical pay a dividend?
Indraprastha Medical offers a trailing dividend yield of about 1.2%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Indraprastha Medical financially healthy?
Indraprastha Medical carries a debt-to-equity ratio of 0.05x and a current ratio of 2.46x, with a market beta of 0.42. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Indraprastha Medical a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Indraprastha Medical (INDRAMEDCO) the key facts are: market cap ₹3,369 Crore, P/E 18.3x, revenue ₹1,483 Crore, 52-week range 342-640.85. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Indraprastha Medical's full fundamentals live
Get Indraprastha Medical's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.